Quinazoline compounds as kinase inhibitors

Abstract

A compound for treating protein kinase-related disease or disorder having a structure of formula (A): wherein X is N or CH; Y is NH, O, or CH; Z is an aryl or a heteroaryl; and R, R, R, and Rare independently H, halo, nitro, cyano, aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, —OR, —C(O)R, —C(O)NRR, —NRC(O)R, —NRR, —S(O)R, —S(O)NRR, —NRS(O)R, —N═CRR, or —NRC(O)NHR, wherein each of Rand R, independently, is H, alkyl, alkenyl, alkynyl, aryl, aryloxy, alkoxy, hydroxy, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, or Rand R, together with the nitrogen atom to which they are bonded, form heteroaryl, heterocycloalkyl, or heterocycloalkenyl; or Rand Rare as defined above, and Rand Rtogether with the carbons, to which they are attached, form a heterocycloalkenyl or heteroaryl.